Market Newsdesk

Optimized capital structure, retiring short-term maturing debt

Well-funded for commercial operations and growth pipeline

NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it drew down US$50 million from its five-year facility provided by existing Mesoblast shareholder and director Dr. Gregory George. Mesoblast had US$122 million cash at March 30, 2026. In aggregate Mesoblast is well funded to invest in its commercial operations and growth pipeline, and optimize its capital structure by retiring the higher cost NovaQuest Capital Management LLC debt facility eliminating the short-term debt obligations.

The credit-line has a fixed interest rate of 8.00% per annum, a substantial reduction from prior facilities, with a five-year interest only period (from initial draw), and will be secured solely with the Temcell¹ royalty. The facility can be repaid at any time without incurring early prepayment or make-whole fees, does not include exit fees.

Mesoblast Chief Executive Silviu Itescu said, “Mesoblast’s balance sheet is strengthened by a favorable long-term facility with elimination of short-term high-cost debt. The facility does not encumber any of our material assets or intellectual property, enabling unrestricted entry into strategic partnerships or licensing transactions.”

About Mesoblast

Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil^® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil^® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

References / Footnotes

1. TEMCELL^® HS Inj. is a registered trademark of JCR Pharmaceuticals Co. Ltd.

Forward-Looking Statements

This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:

New York, N.Y., June 24, 2026 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor and technology company focused on developing clean energy solutions, today announced recent and upcoming high-profile engagements with government officials, industry leaders, multilateral organizations, and energy stakeholders across Asia, Africa, Latin America, and the Caribbean as well as a management team update.

Global Strategic Engagements Across Emerging Nuclear Markets

As part of NANO Nuclear’s efforts to build key relationships, knowledge base, and market presence necessary to support future reactor deployment opportunities across emerging global nuclear markets, NANO Nuclear has actively participated in international forums focused on advancing nuclear innovation, stakeholder engagement, workforce development, supply chain readiness, and deployment planning.

Nuclear Energy Innovation Summit for Africa (NEISA)

May 19 – 21, 2026 | Kigali, Rwanda.

• The summit convened representatives from 24 African nations, alongside international organizations, industry leaders, and government officials, to discuss pathways toward responsible nuclear energy development across the continent.
  • Sarah Lennon, NANO Nuclear’s International Nuclear Policy Advisor, served as a panelist on public and stakeholder engagement, sharing perspectives on the critical role that community outreach, education, transparency, and workforce development play in establishing successful nuclear programs.

Nuclear Energy Institute’s Nuclear Executive Mission to India

May 17 – 21, 2026 | New Delhi & Mumbai, India.

• A delegation of U.S. nuclear industry leaders met with senior government officials, private sector representatives, and stakeholders involved in shaping India’s future energy landscape in New Delhi and Mumbai, expanding the Company’s potential pathways for collaboration, technology deployment, and commercial engagement in one of the world’s fastest-growing energy markets

Latin America and Caribbean Regional Small Modular Reactor Workshop

June 2 – 4, 2026 | Buenos Aires, Argentina.

• The workshop was conducted under the auspices of the U.S. Department of State’s Foundational Infrastructure for Responsible Use of Small Modular Reactor Technology (FIRST) Program, an initiative designed to support countries considering advanced nuclear energy technologies.
  • Leopoldo Garcia, NANO Nuclear’s Project Engineer, contributed to a discussion centered on supply chain development and technology deployment considerations.

Through continued participation in international forums, government-led initiatives, trade missions, and technical workshops, NANO Nuclear remains committed to advancing global nuclear energy development while expanding awareness of its technologies, capabilities, and integrated services across emerging and established nuclear markets.

Management Team Updates: James Walker Takes Role as Interim Head of Reactor Development and Massimiliano Fratoni to Support Lead KRONOS MMR™ Program

As NANO Nuclear continues to expand and execute on its efforts across technology development, regulatory engagement, commercialization, and international stakeholder relationships, NANO Nuclear announced today that James Walker, NANO Nuclear’s Chief Executive Officer, is taking the position as Interim Head of Reactor Development.

In connection with this appointment, the Company announced that Dr. Florent Heidet, Chief Technology Officer and Head of Reactor Development, has departed the Company, effective immediately.

To support Mr. Walker in continuity and execution across NANO Nuclear’s reactor development programs, Prof. Massimiliano Fratoni, NANO Nuclear’s Senior Director and Head of Reactor Design, and Distinguished Professor and Chair of the Department of Nuclear Engineering at the University of California, Berkeley, will take on an expanded leadership role to support the team in continuing the advancement of the prototype KRONOS MMR™ reactor at The University of Illinois as well as plans for ultimate commercial deployment of KRONOS MMR™ reactors. Prof. Fratoni has been working to advance development of the ZEUS™ reactor, another microreactor technology in NANO Nuclear’s portfolio, and will now transition to supporting the KRONOS MMR™ reactor. Prof. Fratoni was also previously awarded the American Nuclear Society’s Untermyer & Cisler Reactor Technology Medals, in recognition of his outstanding contributions to the advancement of nuclear technology, in addition to receipt of the Early Career Physicist Award in 2018.

“We welcome James’ leadership and vision back to our reactor development program on an interim basis and are grateful for the expanded role Prof. Fratoni will be playing. We have greatly expanded our engineering and technical teams over the last year; and will continue our efforts to improve and optimize the execution of our reactor and commercial vertical integration vision,” said Jay Yu, Chairman and President of NANO Nuclear Energy. “These organizational updates are intended to support our next phase of growth as we advance our reactor development, regulatory licensing, commercialization, and strategic engagement objectives.”

About NANO Nuclear Energy Inc.

NANO Nuclear Energy Inc. (NASDAQ: NNE) is a North American advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel supply chain, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services. NANO Nuclear believes it is the first portable nuclear microreactor company to be listed publicly in the U.S.

Led by a world-class nuclear engineering team, NANO Nuclear’s reactor products in development include its lead project, the patented KRONOS MMR^™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement with the U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign (U. of I.), ZEUS^™ system, a solid core battery reactor, and the space focused, portable LOKI MMR^™ system each representing advanced developments in clean energy solutions that are modular, on-demand capable, advanced nuclear microreactors.

Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, bolstered by the May 2026 acquisition of Secured Transportation Services (STS), is led by former executives from the largest transportation company in the world and provides nuclear engineering and materials transport services in the U.S. and globally. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy.

HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a HALEU fuel fabrication pipeline for NANO Nuclear’s own microreactors as well as the broader advanced nuclear reactor industry.

NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear’s developing micro nuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR^™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS’ initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon’s surface.

For more corporate information please visit: https://NanoNuclearEnergy.com/

For further NANO Nuclear information, please contact:

Email: [email protected]
Business Tel: (212) 634-9206

PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE:
NANO Nuclear Energy LINKEDIN
NANO Nuclear Energy YOUTUBE
NANO Nuclear Energy X PLATFORM

Cautionary Note Regarding Forward Looking Statements

This news release, the stakeholder event referred to herein and statements of NANO Nuclear’s management in connection with this news release and such events contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “explore,” “aim,” “plans”, “believes”, “potential”, “will”, “should”, “could”, “would,” “goal,” “aim,” “develop,” “may” or derivatives of these words and other words relating to the future. Specifically, forward-looking statements include those related to NANO Nuclear’s management, development, construction, demonstration, regulatory licensing and commercial plans and strategies and other future plans and intentions (including the anticipated impacts on and benefits to the Company of the departure of Dr. Heidet and the expanded roles of Mr. Walker and Prof. Fratoni as described herein). These and other forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following: (i) risks related to our U.S. Department of Energy (“DOE”), Canadian Nuclear Safety Commission (“CNSC”) or related state or non-U.S. nuclear licensing submissions, (ii) risks related to our vertical integration strategy and the development of new or advanced technology and the acquisition of complimentary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) our ability to obtain contracts and funding to be able to continue operations, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the DOE, the U.S. Nuclear Regulatory Commission, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation, as well as the CNSC, and (vi) similar risks and uncertainties associated with the operating an early stage business a highly regulated and rapidly evolving industry. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

SAN FRANCISCO, June 24, 2026 (GLOBE NEWSWIRE) — On February 20, 2026, GRAIL, Inc. (NASDAQ: GRAL) shed over $2.2 billion of market capitalization after surprising investors with its NHS-Galleri Trial readout. The news caused huge investor losses and triggered a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired shares of GRAIL common stock between May 13, 2025 and February 19, 2026.

National shareholder rights firm Hagens Berman is investigating the alleged claims that GRAIL and its co-defendant executives violated the federal securities laws and encourages GRAIL investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge about GRAIL’s NHS-Galleri Trial to contact the firm’s attorneys.

Class Period: May 13, 2025 – Feb. 19, 2026
Lead Plaintiff Deadline: Aug. 4, 2026
Visit:www.hbsslaw.com/investor-fraud/gral
Contact the Firm Now: [email protected]
                                        844-916-0895

GRAIL, Inc. (GRAL) Securities Class Action:

Commercial stage healthcare company GRAIL focuses on early cancer detection.

The litigation focuses on the propriety of GRAIL’s disclosures about the design of its NHS-Galleri trial (the “trial”) and the likelihood it would meet its primary endpoint – with three consecutive years of follow-up screening, the absolute reduction in the number of late stage (stages 3 and 4) cancer diagnoses.

During the Class Period, GRAIL expressed high confidence in the trial’s design and likely outcomes. They consistently stated that the three-year duration was specifically chosen to demonstrate a statistically significant reduction in combined stage 3 and 4 cancers.

The complaint alleges that GRAIL misled investors by creating the false impression that it possessed reliable information supportive of the probability of the trial achieving its primary endpoint. The complaint further alleges that GRAIL’s expressed optimism was unrealistic because, unknown to investors, the company had information suggesting that three years would be insufficient to support the trial’s achievement of the primary endpoint.

Investors learned the truth on February 19, 2026. That day, the defendants announced that the trial failed to achieve its primary endpoint. Of significant concern was the admission that “we probably should have allowed for a longer follow-up period.”

The market quickly reacted, sending the price of GRAIL shares down over 50% the next day.

“We’re focused on when GRAIL and its management knew that the need for a longer follow-up period diverged from the touted three-year duration,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the pending claims in the filed lawsuit.

If you invested in GRAIL and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.

If you’d like more information and answers to other frequently asked questions about the GRAIL case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding GRAIL should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:

Reed Kathrein, 844-916-0895

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —

— Fanregratinib holds promise as a new treatment option for pretreated advanced ICC patients harboring FGFR2-fusions/rearrangements —

HONG KONG and FLORHAM PARK, N.J., June 25, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces results from the pivotal Phase II registration study of fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (“ICC”) will be presented at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress taking place from July 1 to 4, 2026 in Munich, Germany.

Supported by data from the study, a New Drug Application (NDA) for fanregratinib for the treatment of adult patients with advanced, metastatic or unresectable ICC with fibroblast growth factor receptor (“FGFR”) 2 fusion/rearrangement who have previously received systemic therapy has been accepted for review and granted priority review by the China National Medical Products Administration (NMPA) in December 2025.

“The clinical reality for this patient population with advanced FGFR2–fusion/rearrangement ICC is highly challenging, as the entire cohort had progressed on prior chemotherapy, and a significant majority had prior immunotherapy exposure,” said Professor Jianming Xu of the Chinese PLA General Hospital and leading Principal Investigator of the study. “The results from this registration-enabling trial represent an important milestone in the targeted treatment landscape for FGFR2-altered ICC. The objective response rate and survival metrics achieved by fanregratinib clearly support its therapeutic value as a potent, selective oral treatment option. We are encouraged by these findings and hope to see this innovation translate into clinical practice to address a critical need in gastrointestinal oncology.”

This pivotal study is a single-arm, multi-center, open-label, Phase II registration clinical trial conducted across 53 sites in China to evaluate the efficacy, safety and pharmacokinetic of fanregratinib in treating advanced ICC patients with FGFR2 fusion/rearrangement (NCT04353375). All patients had received at least one line of systemic therapy, of which all had received chemotherapy and 72% had received immunotherapy. The study has met its primary endpoint, demonstrating an Independent Review Committee (IRC)-assessed objective response rate (ORR) of 42.5% (95% CI: 30.0%–53.6%). Key secondary endpoints showed consistent clinical activity and a rapid onset of action, with a median time to response of 1.4 months. Median duration of response (DoR) was 6.9 months (95% CI: 5.6–8.5) and disease control rate (DCR) reached 83.9% (95% CI: 74.5%–90.9%). Furthermore, the median progression-free survival (PFS) was 6.9 months (95% CI: 4.1–8.2), while the median overall survival (OS) was 16.6 months (95% CI: 12.4–16.6).

Fanregratinib exhibited a manageable safety profile consistent with the known mechanism of selective FGFR inhibitors. Drug-related adverse events of Grade 3 or greater were reported in 48.3% of patients, with the most common being elevations in liver enzymes and palmar-plantar erythrodysesthesia syndrome (PPES). Treatment discontinuation due to drug-related adverse events was limited to 2.2% of patients, and no treatment-related deaths were recorded.

Details of the presentation are as follows:

About Fanregratinib

Fanregratinib (HMPL-453) is a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3. Aberrant FGFR signaling has been found to be a driving force in tumor growth, promotion of angiogenesis and resistance to anti-tumor therapies. Abnormal FGFR gene alterations are believed to be the drivers of tumor cell proliferation in several solid tumor settings. HUTCHMED currently retain all rights to fanregratinib worldwide.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fanregratinib, the further clinical development for fanregratinib, its expectations as to whether any studies on fanregratinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fanregratinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fanregratinib for a targeted indication, and the sufficiency of funding. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

All amounts presented in this release are in U.S. Dollar (“USD”) unless otherwise stated.

CALGARY, Alberta, June 24, 2026 (GLOBE NEWSWIRE) — Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) is pleased to announce that the Company has entered into an amended and restated credit agreement dated June 24, 2026 with respect to its syndicated secured revolving credit facility (the “RCF”). The maturity date of the RCF has been extended by three years to June 30, 2029 and availability is unchanged at $800 million. The Company’s limit under the RCF may be increased by up to $200 million at the request of the Company, subject to lenders’ consent, compared to $50 million previously. As at March 31, 2026, the Company had drawn $162 million on its RCF. Led by the Royal Bank of Canada as agent, Enerflex received renewed lending commitments from all current syndicate members.

The Company also continues to maintain a $70 million unsecured credit facility (the “LC Facility”) with one of the lenders in its RCF syndicate. The LC Facility is supported by performance security guarantees provided by Export Development Canada.

Preet Dhindsa, Enerflex’s Senior Vice President and Chief Financial Officer, commented, “We appreciate the continued support of our lending syndicate. The extension of our revolving credit facility solidifies Enerflex’s financial flexibility as we execute our strategy. With a strong balance sheet and ample available liquidity, we remain focused on disciplined capital allocation and delivering long-term value for shareholders.”

Q2 Earnings Release

Enerflex plans to release its financial results and operating highlights for the three and six months ended June 30, 2026, on Thursday, August 6, 2026 prior to market open. Results will be communicated by news release and will be available on the Company’s website at www.enerflex.com and under the electronic profile of the Company on SEDAR+ and EDGAR at www.sedarplus.ca and www.sec.gov/edgar, respectively.

Investors, analysts, members of the media, and other interested parties, are invited to participate in a conference call and audio webcast on Thursday, August 6, 2026 at 8:00 a.m. (MT), where members of senior management will discuss the Company’s results. A question-and-answer period will follow.

To participate, register at https://register-conf.media-server.com/register/BIebea8b6833b642bbbff6b1c892d4954a. Once registered, participants will receive the dial-in numbers and a unique PIN to enter the call. The audio webcast of the conference call will be available on the Enerflex website at www.enerflex.com under the Investors section or can be accessed directly at https://edge.media-server.com/mmc/p/jgxueet4.

ADVISORY REGARDING FORWARD-LOOKING INFORMATION

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” (and together with “forward-looking information”, “FLI”) within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are FLI. The use of any of the words “plan”, “will”, and similar expressions, are intended to identify FLI. In particular, this news release includes (without limitation) FLI pertaining to the Company’s expectation to release its financial results and operating highlights for the three and six months ended June 30, 2026, prior to the markets opening on Thursday, August 6, 2026 along with the news release, conference call and audio webcast associated therewith.

The FLI included in this news release is made as of the date of this news release and is based on the information available to the Company at such time and, other than as required by law, Enerflex disclaims any intention or obligation to update or revise any FLI, whether as a result of new information, future events, or otherwise. This news release and its contents should not be construed, under any circumstances, as investment, tax, or legal advice.

ABOUT ENERFLEX
Enerflex is a leading provider of modular natural gas, power, and treated water technology solutions, delivering value through disciplined execution and a deliberate approach to where we compete. Our customer focused delivery model supports operational excellence, innovation, and scalability across our global footprint with a focus on creating long-term shareholder value.

With approximately 4,400 engineers, manufacturers, technicians, professionals, and innovators, Enerflex is bound together by a shared vision: Transforming Energy for a Sustainable Future. The Company remains committed to the future of natural gas and the critical role it plays, while focused on sustainability offerings to support the world’s energy needs.

Enerflex’s common shares trade on the Toronto Stock Exchange under the symbol “EFX” and on the New York Stock Exchange under the symbol “EFXT”. For more information about Enerflex, visit www.enerflex.com.

For investor and media enquiries, contact:

Paul Mahoney
President and Chief Executive Officer
E-mail: [email protected]

Preet S. Dhindsa
Senior Vice President and Chief Financial Officer
E-mail: [email protected]

Jeff Fetterly
Vice President, Corporate Development and Capital Markets
E-mail: [email protected]